FRAGMATIC: A randomised phase III clinical trial investigating the effect of fragmin® added to standard therapy in patients with lung cancer

BMC Cancer

Volumn 9, Issue , 2009, Pages 355-

  Griffiths, Gareth O ^a,b   Burns, Sarah ^a,b   Noble, Simon I ^a   Macbeth, Fergus R ^c   Cohen, David ^d   Maughan, Timothy S ^a,b  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b Velindre NHS Trust   (United Kingdom)

^c NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE   (United Kingdom)

^d UNIVERSITY OF GLAMORGAN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DALTEPARIN;

ANXIETY; ARTICLE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DEPRESSION; DRUG COST; DYSPNEA; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OPEN STUDY; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; UNITED KINGDOM; VENOUS THROMBOEMBOLISM;

EID: 70449364577     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-9-355     Document Type: Article

References (42)

1. Quinn M, Babb P, Brock A, Kirby L, Jones J. Cancer trends in England and Wales. 2001, London, Stationary Office.
2. Alberg AJ, Samet JM. Epidemiology of Lung Cancer. Chest 2003, 123S:21-49.
3. Samet JM. The epidemiology of lung cancer. Chest 1993, 103:20-25.
4. Alifano M, Benedetti G, Trisolini R. Can low-molecular-weight heparin improve the outcome of patients with operable non-small cell lung cancer?: an urgent call for research. Chest 2004, 126:601-607. 10.1378/chest.126.2.601, 15302749.
5. Kakkar VV, Howe CT, Nicolaides AN, Renney JTG, Clarke MB. Deep vein thrombosis of the leg. Is there a "high risk" group?. American Journal of Surgery 1970, 120:527-530. 10.1016/S0002-9610(70)80023-X, 4097038.
6. Kakkar AK, de Lorenzo F, Pineo GF, Williamson RC. Venous thrombosis and cancer. Baillieres Clin Haematol 1998, 11:675-687. 10.1016/S0950-3536(98)80089-9, 10331099.
7. Kakkar AK, Williamson RC. Antithrombotic therapy in cancer. BMJ 1999, 318:1571-1572. 1115952, 10364099.
8. Lee AY, Levine MN. Venous Thromboembolism and Cancer: Risks and Outcomes. Circulation 2003, 107:17-21. 10.1161/01.CIR.0000047062.03282.A3, 12515735.
9. Bick RL. Alterations of hemostasis associated with malignancy: etiology, pathophysiology, diagnosis and management. Semin Thromb Hemost 1978, 5:1-26.
10. Johnson MJ, Sproule MW, Paul J. The prevalence and associated variables of deep venous thrombosis in patients with advanced cancer. Journal of Clinical Oncology 1999, 11:105-110.
11. Levitan N, Dowlatic A, Remick SC, Tahsilda HI, Sivinski LD, Beyth R, Rimm AA. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine 1999, 78:285-291. 10.1097/00005792-199909000-00001, 10499070.
12. Alikhan R, Cohen AT, Combe S, Samama MM, Desjardins L, Eldor A, Janbon C, Leizorovicz A, Olsson CG, Turpie AG. Prevention of venous thromboembolism in medical patients with enoxaparin: a subgroup analysis of the MEDENOX study. Blood Coagulation Fibrinolysis 2003, 14:341-346. 10.1097/00001721-200306000-00004, 12945875.
13. Buccheri G, Ferrigno D, Ginardi C, Zuliani C. Haemostatic abnormalities in lung cancer: prognostic implications. Eur J Cancer 1998, 33:50-55.
14. Seitz R, Heidtmann HH, Wolf M, Immel A, Egbring R. Prognostic impact of an activation of coagulation in lung cancer. Ann Oncol 1997, 9:1255-1256.
15. Sorensen HT, Mellemkjaer L, Olsen JH, Nielsen GL. Prognosis of cancers associated with venous thromboembolism. N Engl J Med 2000, 343:1846-1850. 10.1056/NEJM200012213432504, 11117976.
16. Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, Rickles FR, Julian JA, Math M, Haley S, Kovacs MJ, Gent M. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003, 349:146-153. 10.1056/NEJMoa025313, 12853587.
17. Wolf RA. Are patients with cancer receiving adequate thromboprophylaxis? results from FRONTLINE. Cancer Treat Rev 2003, 29:7-9. 10.1016/S0305-7372(03)80002-6, 12887943.
18. Kirwan CC. Prophylaxis for venous thromboembolism during treatment for cancer: questionnaire survey. BMJ 2003, 327:597-598. 10.1136/bmj.327.7415.597, 194089, 12969928.
19. Donati M. Cancer and thrombosis: from Phlegmasia alba dolens to transgenic mice. Thromb Haemost 1995, 74:278-281.
20. Mousa S. Anitcoagulants in thrombosis and cancer: the missing link. Semin Thromb Hemost 2002, 28:45-52. 10.1055/s-2002-20559, 11885025.
21. Gouin-Thibault I, Samama MM. Laboratory analysis of the thrombophilic state in cancer patients. Semin Thromb Hemost 1999, 25:167-172. 10.1055/s-2007-994918, 10357084.
22. Falanga A, Rickles FR. Pathophysiology of the thrombophilic state in the cancer patient. Semin Thromb Hemost 1999, 25:173-182. 10.1055/s-2007-994919, 10357085.
23. Bromberg M, Capello M. Cancer and blood coagulation: molecular aspects. Cancer J Sci Am 1999, 5:132-138.
24. Zacharski L, Ornstein D. Heparin and cancer. Thromb Haemost 1998, 80:10-23.
25. Kakkar AK, Hedges AR, Williamson RCN, Kakkar VV. Perioperative herparin therapy inhibits late death from metastatic cancer. Int J Oncol 1995, 6:885-888.
26. Lebeau B, Chastang C, Brechot JM, Capron F, Dautzenberg B, Delaisements C, Mornet M, Brun J, Hurdebourcq, Lemarie E. Subcutaneous heparin treatment increases survival in small cell lung cancer "Petit Cellules" Group. Cancer 1994, 74:38-45. 10.1002/1097-0142(19940701)74:1<38::AID-CNCR2820740108>3.0.CO;2-E, 8004580.
27. Altinbas M, Coskun HS, Er O. A randomised clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. J Thromb Haemost 2004, 2:1266-1271. 10.1111/j.1538-7836.2004.00871.x, 15304029.
28. Kakkar AK, Levine MN, Kadziola Z, Lemoine NR, Low V, Patel HK, Rustin G, Thomas M, Quigley M, Williamson RCN. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol 2004, 22:1944-1948. 10.1200/JCO.2004.10.002, 15143088.
29. Hejna M, Raderer M, Zielinski CC. Inhibition of metastases by anticoagulants. J Nati Cancer Inst 1999, 91:22-36.
30. Hirsh J. Heparin. N Engl J Med 1991, 324:1565-1574.
31. Iruela-Arispe ML, Dvorak HF. Angiogenesis: a dynamic balance of stimulators and inhibitors. Thromb Haemost 1997, 78:672-677.
32. Folkman J. Seminars in medicine of the Beth Israel Hospital in Boston. N Engl J Med 1995, 333:1757-1763. 10.1056/NEJM199512283332608, 7491141.
33. Bennett MR, Evan GI, Newby AC. Deregulated expression of the c-myc oncogene abolishes inhibition of proliferation of rat vascular smooth muscle cells by serum reduction, interferon-gamma, heparin, and cyclic nucleotide analogues and induces apoptosis. Circ Res 1994, 74:525-536.
34. Wang A, Templeton DM. Inhibition of mitogenesis and c-fos induction in mesanglial cells by heparin and heparin sulfates. Kidney Int 1996, 49:437-438. 10.1038/ki.1996.63, 8821828.
35. Mousa S. The low molecular weight heparin, tinzaparin, in thrombosis and beyond. Cardiovasc Drug Rev 2002, 20:163-180.
36. Mousa A, Mohamed S. Antiangiogenic mechanisms and efficacy of the low molecular weight heparin, tinzaparin: anticancer efficacy. Oncol Rep 2004, 12(4):683-688.
37. Khorana AA, Sahni A, Altland OD, Francis CW. Heparin inhibition of endothelial cell proliferation and organization is dependent on molecular weight. Arterioscler Thromb Vasc Biol 2003, 1:2110-2115.
38. Vlodavsky I, Ishai-Michaeli R, Mohsen M, Bar-Shavit R, Catane R, Ekre HP, Svahn CM. Modulation of neovasculaization and metastasis by species of heparin. Adv Exp Med Biol 1992, 313:317-327.
39. Ekre HP, Naparstek Y, Lider O, Hyden P, Hagermark O, Nilsson T, Vlodavsky I, Cohen I. Anti-inflammatory effects of heparin and its derivatives: inhibition of complement and of lymphocyte migration. Adv Exp Med Biol 1992, 313:329-340.
40. Bergqvist D, Burmark US, Flordal PA, Frisell J, Hallbook T, Hedberg M. Low molecular weight heparin started before surgery as prophylaxis against deep vein thrombosis: 2,500 versus 5,000 XaI units in 2070 patients. Br J Surg 1995, 82:496-501. 10.1002/bjs.1800820421, 7613894.
41. Royston A, Babiker A. A menu driven facility for complex sample size calculation in randomised controlled trials with a survival or a binary outcome. Stata Journal 2002, 2:151-163.
42. Dunn G, Maracy M, Dowrick C, Ayuso-Mateos JL, Dalgard OS, Page H, Lehtinen V. Estimating psychological treatment effects from a randomised controlled trial with both non-compliance and loss to follow up. British Journal of Psychiatry 2003, 183:323-331. 10.1192/bjp.183.4.323, 14519610.